Here's the article: It least it seems to bolster ENML's claims. A good day for ENML
Journal of Clinical Dentistry
Publishes Special Issue on Enamelon
Technology
CRANBURY, N.J.--(BUSINESS WIRE)--July 19, 1999--Enamelon, Inc. (Nasdaq NM: ENML - news), which is using its proprietary ''remineralization'' technology to develop over-the-counter oral products to help stop cavities before they begin, today announced that a Special Issue of the Journal of Clinical Dentistry on ''Advanced Remineralization Technology in Oral Care'' has been released
for publication.
The issue includes ten peer-reviewed papers presenting independent laboratory studies and human
clinical trials of Enamelon's technology at various universities and research institutions. The lead
article, ''Dental Applications of Amorphous Calcium Phosphates,'' authored by Dr. F.C. Eichmiller,
Director of the American Dental Association Health Foundation, and Dr. M.S. Tung, demonstrates
how the soluble calcium, phosphate and fluoride formula of Enamelon® toothpaste can be of benefit
for remineralization therapy. Other papers further discuss Enamelon® toothpaste's remineralizing
capabilities, its ability to re-strengthen enamel damaged by exposure to an acidic beverage, its effects
on fluoride uptake and enamel solubility reduction, and its ability to reduce the size of white spots
after orthodontic banding.
Dr. Steven Fox, CEO, stated that ''the results of these studies provide strong proof of the benefits
of Enamelon® fluoride toothpaste. These studies show that, among other benefits, Enamelon®
toothpaste remineralizes early lesions in tooth enamel, strengthens weakened teeth, and visibly
reduces the area of white spots. Our clinical program is continuing and we expect to release the
results of additional studies in the near future.''
Enamelon, Inc. is focused on developing and marketing over-the-counter oral products based on
proprietary formulations and technologies. The Company's remineralization technologies are
designed to provide the active ingredient fluoride in a formulation containing soluble calcium and
phosphate to advance the fight against tooth decay. The Company's offices are located in Cranbury,
New Jersey.
This release contains forward-looking information and therefore it necessarily involves risks and
uncertainties. Factors that could cause actual events to differ materially from these forward-looking
statements include, but are not limited to, the following: acceptance of the Company's products by
consumers; the inherent limitations of market research and accuracy of syndicated data purchased by
the Company; declines in the Company's sales from current levels; the success of the Company's
revised marketing program; the Company's ability to produce additional financing, as necessary to
maintain its operations until it becomes profitable; and changes in government regulations as they
apply to the Company's products These and other risks are described in the Company's filings with
the Securities and Exchange Commission, including the Company's Form S-1 and Form S-3
registration statements, Annual Report on Form 10-KSB for the year ended December 31,1998,
and 1999 Quarterly Reports on Form 10-Q.
NOTE: Further information on Enamelon is available through our website on the World Wide Web
at enamelon.com
Contact:
ENAMELON, INC.
Edwin Diaz
Vice President-Finance &
Chief Financial Officer
609-395-6900 |
